| Authors: |
Ghazali N; International Society of Liquid Biopsy (ISLB) Young Committee, Spain.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.; Department of Medicine, University of Toronto, Canada.; Cross Cancer Institute, Edmonton, Canada., Ortega-Franco A; International Society of Liquid Biopsy (ISLB) Young Committee, Spain.; The Christie NHS Foundation Trust, Manchester, United Kingdom., de Miguel-Perez D; GENYO Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Liquid Biopsy and Cancer Interception Group, Granada, Spain.; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain., Saldanha EF; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.; Department of Medicine, University of Toronto, Canada., Venetis K; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy., Pisapia P; Department of Public Health, University of Naples Federico II, Naples, Italy., Singhal S; Division of Hematology/Oncology, Department of Medicine, University of California, Davis, California, USA., Bleiberg BA; Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, USA., Reduzzi C; International Society of Liquid Biopsy (ISLB) Young Committee, Spain.; Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA., Borea R; International Society of Liquid Biopsy (ISLB) Young Committee, Spain.; Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy.; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA. |
